rAAV CLN2 Gene Therapy for Durable CNS TPP1 Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for CLN2 disease, such as enzyme replacement therapy (ERT) with Brineura®, require frequent administration and have limited efficacy due to short half-lives in the central nervous system, necessitating a need for durable and long-term TPP1 enzymatic activity without high patient burden.
Innovation Solution
A codon-optimized nucleic acid sequence encoding human tripeptidyl peptidase 1 (TPP1) is delivered using a recombinant adeno-associated virus (rAAV) vector, which includes an AAV capsid and a vector genome with AAV 5′ and 3′ ITRs, designed for intracerebroventricular or intrathecal delivery to provide sustained TPP1 expression in the CNS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy with Brineura is administered, then TPP1 enzymatic activity is provided, but frequent administration is required due to short half-life in the central nervous system
Solution Approach 1:
The patent uses a recombinant adeno-associated virus (rAAV) vector as an intermediary delivery system to transport the CLN2 gene into CNS cells. The viral vector serves as a mediator that establishes long-term gene expression, eliminating the need for frequent enzyme replacement infusions while maintaining reliable TPP1 enzymatic activity.
Solution Approach 2:
The patent replaces the mechanical system of repeated intracerebroventricular infusions with a genetic system. Instead of mechanically administering enzyme protein multiple times, the therapy introduces functional DNA that autonomously produces TPP1 enzyme within cells, achieving sustained enzymatic activity without repeated mechanical interventions.
2Reliability
If frequent administration of Brineura is performed, then TPP1 activity is maintained, but patient burden increases
Solution Approach 1:
The rAAV-mediated gene therapy enables the patient's own cells to produce TPP1 enzyme autonomously. The introduced gene directs cellular machinery to synthesize the functional enzyme, making the system self-sustaining and eliminating the need for continuous external administration or high patient burden.
Solution Approach 2:
The gene therapy establishes continuous TPP1 production within CNS cells from a single administration. The viral vector integrates or persists in host cells, providing uninterrupted enzymatic activity over time, thereby replacing the discontinuous pattern of frequent infusions with sustained therapeutic action.
3Productivity
If Brineura is administered every two weeks, then some clinical benefit is achieved, but durable long-term activity is not sustained
Solution Approach 1:
The therapy performs preliminary action by introducing the functional CLN2 gene into CNS cells before the disease progresses further. This preemptive genetic modification establishes long-term enzymatic activity that outlasts the temporary effect of Brineura infusions, providing durable clinical benefit.
Solution Approach 2:
The patent changes the fundamental parameter of therapy delivery from protein-based (Brineura) to gene-based (rAAV-CLN2). This parameter change transforms the temporal profile of enzyme activity from short-lived and frequency-dependent to long-lasting and administration-independent, achieving both clinical benefit and durability.
Data Source
AI summary
Provided herein are methods and compositions for treatment of Batten disease. Such compositions include a recombinant adeno-associated virus (rAAV), said rAAV comprising an AAV capsid, and a vector genome packaged therein, said vector genome comprising (a) an AAV 5′ inverted terminal repeat (ITR) sequence; (b) a promoter; (c) a CLN2 coding sequence encoding a human TPP1; (d) an AAV 3′ ITR.